Atlas Trials

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Clinical trial NCT04446000 · TERMINATED

Trial details

NCT number
NCT04446000
Sponsor
CSL Behring
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Immune Complex-mediated Autoimmune Diseases
Start date
2020-09-23
Primary completion
2023-03-28
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.